Actions and interactions of the IGF system in Alzheimer's disease: Review and hypotheses

Growth Hormone and IGF Research

Volumn 10, Issue 1, 2000, Pages 1-13

  Lackey, Brett R ^a   Gray, Sandra L ^a   Henricks, Donald M ^a  

^a CLEMSON UNIVERSITY   (United States)

Author keywords

Alzheimer's; Apoptosis; Cytokine; Diabetes; IGF

Indexed keywords

CASPASE; PROTEIN BCL 2; SOMATOMEDIN;

ALZHEIMER DISEASE; APOPTOSIS; DIABETES MELLITUS; DIABETOGENESIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MITOCHONDRION; NEUROPROTECTION; NONHUMAN; NUTRITION; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW;

EID: 0034080888     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1054/ghir.1999.0129     Document Type: Review

References (184)

1. Horsburgh K., Saitoh T. Altered signal transduction in Alzheimer disease. Terry R. D., Katzman R., Bick K. L. Alzheimer's Disease. 1994;387-404 Raven Press, New York, NY.
2. Meier-Ruge W., Bertoni-Freddari C. The significance of glucose turnover in the brain in the pathogenetic mechanisms of Alzheimer's disease. Rev Neurosci. 7:1996;1-19.
3. Ebadi M., Bashir R. M., Heidrick M. L. Neurotrophins and their receptors in nerve injury and repair. Neurochem Int. 30:1997;347-374.
4. Doré S., Kar S., Quirion R. Rediscovering an old friend, IGF-I: potential use in the treatment of neurodegenerative diseases. Trends Neurosci. 20:1997;326-331.
5. Connor B., Beilharz E. J., Williams C. Insulin-like growth factor-I (IGF-I) immunoreactivity in the Alzheimer's disease temporal cortex and hippocampus. Brain Res Mol Brain Res. 49:1997;283-290.
6. D'Ercole A. J., Ye P., Calikoglu A. S., Gutierrez-Ospina G. The role of insulin-like growth factors in the central nervous system. Mol Neurobiol. 13:1996;227-255.
7. Folli F., Bonfanti L., Renard E., Kahn C. R., Merighi A. Insulin receptor substrate-1 (IRS-1) distribution in the rat central nervous system. J Neurosci. 14:1994;6412-6422.
8. 125I]insulin receptor binding sites in the hippocampus of aged memory-unimpaired and -impaired rats. Neuroscience. 80:1997;1033-1040.
9. Ye P., Umayahara Y., Ritter D. Regulation of insulin-like growth factor I (IGF-I) gene expression in brain of transgenic mice expressing an IGF-I-luciferase fusion gene. Endocrinology. 138:1997;5466-5475.
10. Reinhardt R. R., Bondy C. A. Insulin-like growth factors cross the blood-brain barrier. Endocrinology. 135:1994;1753-1761.
11. Nilsson C., Lindvall-Axelsson M., Owman C. Neuroendocrine regulatory mechanisms in the choroid plexus-cerebrospinal fluid system. Brain Res Brain Res Rev. 17:1992;109-138.
12. Duffy K. R., Pardridge W. M., Rosenfeld R. G. Human blood-brain barrier insulin-like growth factor receptor. Metabolism. 37:1988;136-140.
13. Frank H. J., Pardridge W. M., Morris W. L., Rosenfeld R. G., Choi T. B. Binding and internalization of insulin and insulin-like growth factors by isolated brain microvessels. Diabetes. 35:1986;654-661.
14. Lin X., Bulleit R. F. Insulin-like growth factor I (IGF-I) is a critical trophic factor for developing cerebellar granule cells. Brain Res Dev Brain Res. 99:1997;234-242.
15. Walter H. J., Berry M., Hill D. J., Logan A. Spatial and temporal changes in the insulin-like growth factor (IGF) axis indicate autocrine/paracrine actions of IGF-I within wounds of the rat brain. Endocrinology. 138:1997;3024-3034.
16. Torres-Aleman I., Barrios V., Berciano J. The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis. Neurology. 50:1998;772-776.
17. Torres-Aleman I., Barrios V., Lledo A., Berciano J. The insulin-like growth factor I system in cerebellar degeneration. Ann Neurol. 39:1996;335-342.
18. Fernandez A. M., de la Vega A. G., Torres-Aleman I. Insulin-like growth factor I restores motor coordination in a rat model of cerebellar ataxia. Proc Natl Acad Sci USA. 95:1998;1253-1258.
19. Contreras P. C., Vaught J. L., Gruner J. A. Insulin-like growth factor-I prevents development of a vincristine neuropathy in mice. Brain Res. 774:1997;20-26.
20. Loddick S. A., Liu X. J., Lu Z. X. Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke. Proc Natl Acad Sci USA. 95:1998;1894-1898.
21. Cohen P., Ocrant I., Fielder P. J. Insulin-like growth factors (IGFs): implications for aging. Psychoneuroendocrinology. 17:1992;335-342.
22. Behrman H. R., Preston S. L., Aten R. F., Rinaudo P., Zreik T. G. Hormone induction of ascorbic acid transport in immature granulosa cells. Endocrinology. 137:1996;4316-4321.
23. Zumkeller W., Muller D., Muller S., Gunther C., Westphal M. Expression and synthesis of insulin-like growth factor-binding proteins in human glioma cell lines. Int J Oncol. 12:1998;129-135.
24. Ni W., Rajkumar K., Nagy J. I., Murphy L. J. Impaired brain development and reduced astrocyte response to injury in transgenic mice expressing IGF binding protein. Brain Res. 769:1997;97-107.
25. Rajkumar K., Barron D., Lewitt M. S., Murphy L. J. Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice. Endocrinology. 136:1995;4029-4034.
26. 3H]2DG study. Neuroreport. 8:1997;2907-2911.
27. Beck K. D., Powell-Braxton L., Widmer H. R., Valverde J., Hefti F. Igf1 gene disruption results in reduced brain size. CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron. 14:1995;717-730.
28. Doré S., Kar S., Quirion R. Insulin-like growth factor-I protects and rescues hippocampal neurons against beta-amyloid- and human amylin-induced toxicity. Proc Natl Acad Sci USA. 94:1997;4772-4777.
29. 125I]insulin receptor binding sites in the rat hippocampal formation. Neuroscience. 55:1993;69-80.
30. Mattson M. P., Zhang Y., Bose S. Growth factors prevent mitochondrial dysfunction, loss of calcium homeostasis, and cell injury, but not ATP depletion in hippocampal neurons deprived of glucose. Exp Neurol. 121:1993;1-13.
31. Imahori K., Uchida T. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J Biochem. 121:1997;179-188.
32. Hong M., Lee V. M. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem. 273:1997;19547-19553.
33. Shaw M., Cohen P., Alessi D. R. Further evidence that the inhibition of glycogen synthase kinase-3beta by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. FEBS Lett. 416:1997;307-311.
34. Hwang O., Choi H. J. Induction of gene expression of the catecholamine-synthesizing enzymes by insulin-like growth factor-I. J Neurochem. 54:1996;1988-1996.
35. Masters B. A., Werner H., Roberts C. T. Jr, LeRoith D., Raizada M. K. Developmental regulation of insulin-like growth factor-I-stimulated glucose transporter in rat brain astrocytes. Endocrinology. 128:1991;2548-2557.
36. Sherrard R. M. Insulin-like growth factor-I induces climbing fibre re-innervation of the rat cerebellum. Neuroreport. 8:1997;3225-3228.
37. Saatman K. E., Contreras P. C., Smith D. H. Insulin-like growth factor-I (IGF-I) improves both neurological motor and cognitive outcome following experimental brain injury. Exp Neurol. 147:1997;418-427.
38. Barinaga M. Is apoptosis key in Alzheimer's disease. Science. 281:1998;1303-1304.
39. Sayre L. M., Zagorski M. G., Surewicz W. K., Krafft G. A., Perry G. Mechanisms of neurotoxicity associated with amyloid beta deposition and the role of free radicals in the pathogenesis of Alzheimer's disease: a critical appraisal. Chem Res Toxicol. 10:1997;518-526.
40. Mattson M. P., Partin J., Begley J. G. Amyloid beta-peptide induces apoptosis-related events in synapses and dendrites. Brain Res. 807:1998;167-176.
41. Tucker H. M., Rydel R. E., Wright S., Estus S. Human amylin induces "apoptotic" pattern of gene expression concomitant with cortical neuronal apoptosis. J Neurochem. 71:1998;506-516.
42. Kim T. W., Pettingell W. H., Jung Y. K., Kovacs D. M., Tanzi R. E. Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. Science. 277:1997;373-376.
43. Williams L. R. Oxidative stress, age-related neurodegeneration, and the potential for neurotrophic treatment. Cerebrovasc Brain Metab Rev. 7:1995;55-73.
44. Clutton S. The importance of oxidative stress in apoptosis. Brit Med Bull. 53:1997;662-668.
45. Pasinetti G. M., Aisen P. S. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience. 87:1998;319-324.
46. Papanicolaou D. A., Wilder R. L., Manolagas S. C., Chrousos G. P. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 128:1998;127-137.
47. Evan G., Littlewood T. A matter of life and cell death. Science. 281:1998;1317-1321.
48. Adams J. M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 281:1998;1322-1326.
49. Hara H., Friedlander R. M., Gagliardini V. Inhibition of interleukin-1 beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci USA. 94:1997;2007-2012.
50. Cheng Y., Deshmukh M., D'Costa A. Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. J Clin Invest. 101:1998;1992-1999.
51. Fink K., Zhu J., Namura S. Prolonged therapeutic window for ischemic brain damage caused by delayed caspase activation. J Cereb Blood Flow Metab. 18:1998;1071-1076.
52. Namura S., Zhu J., Fink K. Activation and cleavage of caspase-3 in apoptosis induced by experimental cerebral ischemia. J Neurosci. 18:1998;3659-3668.
53. Endres M., Namura S., Shimizu-Sasamata M. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J Cereb Blood Flow Metab. 18:1998;238-247.
54. Kitamura Y., Shimohama S., Kamoshima W. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Res. 780:1998;260-269.
55. MacGibbon G. A., Lawlor P. A., Sirimanne E. S. Bax expression in mammalian neurons undergoing apoptosis, and in Alzheimer's disease hippocampus. Brain Res. 750:1997;223-234.
56. Tamatani M., Ogawa S., Tohyama M. Roles of Bcl-2 and caspases in hypoxia-induced neuronal cell death: a possible neuroprotective mechanism of peptide growth factors. Brain Res Mol Brain Res. 58:1998;27-39.
57. Stroemer R. P., Rothwell N. J. Exacerbation of ischemic brain damage by localized striatal injection in interleukin-1 beta in the rat. J Cereb Blood Flow Metab. 18:1998;833-839.
58. Reed J. C., Jurgensmeier J. M., Matsuyama S. Bcl-2 family proteins and mitochondria. Biochim Biophys Acta. 1366:1998;127-137.
59. Tanaka M., Sawada M., Miura M., Marunouchi T. Insulin-like growth factor-I analogue prevents apoptosis mediated through an interleukin-1 beta converting enzyme (caspase-1)-like protease of cerebellar external granular layer neurons: developmental stage-specific mechanisms of neuronal cell death. Neuroscience. 84:1998;89-100.
60. Wang L., Ma W., Markovich R., Lee W. L., Wang P. H. Insulin-like growth factor I modulates induction of apoptotic signaling in H9C2 cardiac muscle cells. Endocrinology. 139:1998;1354-1360.
61. Russell J. W., Windebank A. J., Schenone A., Feldman E. L. Insulin-like growth factor-I prevents apoptosis in neurons after nerve growth factor withdrawal. J Neurobiol. 36:1998;455-467.
62. Feldman E. L., Sullivan K. A., Kim B., Russell J. W. Insulin-like growth factors regulate neuronal differentiation and survival. Neurobiol Dis. 4:1997;201-214.
63. Kulik G., Weber M. J. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol. 18:1998;6711-6718.
64. Weihl C. C., Ghadge G. D., Kennedy S. G., Hay N., Miller R. J., Roos R. P. Mutant presenilin-1 induces apoptosis and downregulates Akt/PKB. J Neurosci. 19:1999;5360-5369.
65. Jung Y., Miura M., Yuan J. Suppression of interleukin-1 beta-converting enzyme-mediated cell death by insulin-like growth factor. J Biol Chem. 271:1996;5112-5117.
66. de la Monte S. M., Sohn Y. K., Ganju N., Wands J. R. P53- and CD95-associated apoptosis in neurodegenerative diseases. Lab Invest. 78:1998;401-411.
67. Kitamura Y., Shimohama S., Kamoshima W. Changes of p53 in the brains of patients with Alzheimer's disease. Biochem Biophys Res Commun. 232:1997;418-421.
68. Mowat M. R. p53 in tumor progression: life, death, and everything. Adv Cancer Res. 74:1998;25-48.
69. Buckbinder L., Talbott R., Velasco-Miguel S. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature. 377:1995;646-649.
70. Oh Y. IGFBPs and neoplastic models. New concepts for roles of IGFBPs in regulation of cancer cell growth. Endocrine. 7:1997;111-113.
71. Vito P., Ghayur T., D'Adamio L. Generation of anti-apoptotic presenilin-2 polypeptides by alternative transcription, proteolysis, and caspase-3 cleavage. J Biol Chem. 272:1997;28315-28320.
72. Benigni F., Sacco S., Aloe L., Ghezzi P. Intracerebroventricular injection of anti-Fas activates the hypothalamus-pituitary-adrenal axis and induces peripheral interleukin-6 and serum amyloid A in mice: comparison with other ligands of the tumor necrosis factor/nerve growth factor receptor superfamily. Am J Pathol. 153:1998;1377-1381.
73. Harrison M., Dunger A. M., Berg S. Growth factor protection against cytokine-induced apoptosis in neonatal rat islets of Langerhans: role of Fas. FEBS Lett. 435:1998;207-210.
74. Kaipia A., Hsueh A. J. Regulation of ovarian follicle atresia. Annu Rev Physiol. 59:1997;349-363.
75. Okuda Y., Bernard C. C., Fujimura H., Yanagihara T., Sakoda S. Fas has a crucial role in the progression of experimental autoimmune encephalomyelitis. Mol Immunol. 35:1998;317-326.
76. Roulston A., Reinhard C., Amiri P., Williams L. T. Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor alpha. J Biol Chem. 273:1998;10232-10239.
77. Okubo Y., Blakesley V. A., Stannard B., Gutkind S., Le Roith D. Insulin-like growth factor-I inhibits the stress-activated protein Kinase/c-Jun N-terminal kinase. J Biol Chem. 273:1998;25961-25966.
78. Srinivasan A., Li F., Wong A. et al. Bcl-xL functions downstream of caspase-8 to inhibit Fas- and tumor necrosis factor receptor 1-induced apoptosis of MCF7 breast carcinoma cells. J Biol Chem. 273:1998;4523-4529.
79. Hueber A. O., Zornig M., Lyon D., Suda T., Nagata S., Evan G. I. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science. 278:1997;1305-1309.
80. Green D. R., Reed J. C. Mitochondria and apoptosis. Science. 281:1998;1309-1312.
81. Cai J., Jones D. P. Superoxide in apoptosis. Mitochondrial generation triggered by cytochrome c loss. J Biol Chem. 273:1998;11401-11404.
82. Hirsch T., Susin S. A., Marzo I., Marchetti P., Zamzami N., Kroemer G. Mitochondrial permeability transition in apoptosis and necrosis. Cell Biol Toxicol. 14:1998;141-145.
83. Kluck R. M., Bossy-Wetzel E., Green D. R., Newmeyer D. D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 275:1997;1132-1136.
84. Susin S. A., Zamzami N., Kroemer G. Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta. 1366:1998;151-165.
85. Mignotte B., Vayssiere J. L. Mitochondria and apoptosis. Eur J Biochem. 252:1998;1-15.
86. Montal M. Mitochondria, glutamate neurotoxicity and the death cascade. Biochim Biophys Acta. 1366:1998;113-126.
87. Vander Heiden M. G., Chandel N. S., Williamson E. K., Schumacker P. T., Thompson C. B. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell. 91:1997;627-637.
88. 2+: their relationship to apoptosis and oncogenesis. FEBS Lett. 325:1993;104-107.
89. Pastorino J. G., Chen S. T., Tafani M., Snyder J. W., Farber J. L. The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition. J Biol Chem. 273:1998;7770-7775.
90. Kruman I., Bruce-Keller A. J., Bredesen D., Waeg G., Mattson M. P. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J Neurosci. 17:1997;5089-5100.
91. Sayre L. M., Zelasko D. A., Harris P. L., Perry G., Salomon R. G., Smith M. A. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem. 68:1997;2092-2097.
92. Smith M. A., Taneda S., Richey P. L. Advanced Maillaird reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA. 91:1994;5710-5714.
93. Finch C. E., Cohen D. M. Aging, metabolism and Alzheimer disease: Review and hypotheses. Exp Neurology. 143:1997;82-102.
94. Lezoualc'h F., Behl C. Activation of the transcription factor NF-kB as one common molecular signal induced by amyloid b, amylin and hydrogen peroxide. Alzheimer's Res. 3:1997;43-50.
95. Tagami M., Yamagata K., Nara Y. Insulin-like growth factors prevent apoptosis in cortical neurons isolated from stroke-prone spontaneously hypertensive rats. Lab Invest. 76:1997;603-612.
96. Tatton W. G., Chalmers-Redman R. M. Mitochondria in neurodegenerative apoptosis: an opportunity for therapy? Ann Neurol. 44 (3 Suppl.1):1998;S134-S141.
97. Atlante A., Gagliardi S., Marra E., Calissano P. Neuronal apoptosis in rats is accompanied by rapid impairment of cellular respiration and is prevented by scavengers of reactive oxygen species. Neurosci Lett. 245:1998;127-130.
98. Castilla-Cortazar I., Garcia M., Muguerza B. Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis. Gastroenterology. 113:1997;1682-1691.
99. Sortino M. A., Canonico P. L. Neuroprotective effect of insulin-like growth factor I in immortalized hypothalamic cells. Endocrinology. 137:1996;1418-1422.
100. Zhang W., Ghetti B., Lee W. H. Decreased IGF-I gene expression during the apoptosis of Purkinje cells in pcd mice. Brain Res Dev Brain Res. 98:1997;164-176.
101. Lieb K., Fiebich B. L., Schaller H., Berger M., Bauer J. Interleukin-1 beta and tumor necrosis factor-alpha induce expression of alpha 1-antichymotrypsin in human astrocytoma cells by activation of nuclear factor-kappa B. J Neurochem. 67:1996;2039-2044.
102. Shambaugh G. E. I. I. I., Lee R. J., Watanabe G. Reduced cyclin D1 expression in the cerebella of nutritionally deprived rats correlates with developmental delay and decreased cellular DNA synthesis. J Neuropathol Exp Neurol. 55:1996;1009-1020.
103. Khalsa D. S. Integrated medicine and the prevention and reversal of memory loss. Altern Ther Health Med. 4:1998;38-43.
104. Grilli M., Pizzi M., Memo M., Spano P. F. Neuroprotection by aspirin and sodium salicylate through blockade of NF-KB activation. Science. 274:1996;1383-1385.
105. Di Battista J. A., Doré S., Morin N., He Y., Pelletier J. P., Martel-Pelletier J. Prostaglandin E2 stimulates insulin-like growth factor binding protein-4 expression and synthesis in cultured human articular chondrocytes: possible mediation by Ca(++)-calmodulin regulated processes. J Cell Biochem. 65:1997;408-419.
106. Pash J. M., Canalis E. Transcriptional regulation of insulin-like growth factor-binding protein-5 by prostaglandin E2 in osteoblast cells. Endocrinology. 37:1996;2375-2382.
107. Pruzanski W., Stefanski E., Vadas P., Kennedy B. P., van den Bosch H. Regulation of the cellular expression of secretory and cytosolic phospholipases A2, and cyclooxygenase-2 by peptide growth factors. Biochim Biophys Acta. 1403:1998;47-56.
108. Bui T., Straus D. S. Effects of cyclopentenone prostaglandins and related compounds on insulin-like growth factor-I and Waf1 gene expression. Biochim Biophys Acta. 1397:1998;31-42.
109. Prassad K. N., Howland A. R., La Rosa F. G., Howland P. G. Prostaglandins as putative neurotoxins in Alzheimer's Disease. Proc Soc Exp Biol Med. 219:1998;120-125.
110. Jain S., Golde D. W., Bailey R., Geffner M. E. Insulin-like growth factor-I resistance. Endocr Rev. 19:1998;625-646.
111. Menon R. K., Sperling M. A. Insulin as a growth factor. Endocrinol Metab Clin North Am. 25:1996;633-647.
112. Janssen J. A., Stolk R. P., Pols H. A., Grobbee D. E., Lamberts S. W. Serum free and total insulin-like growth factor-I, insulin-like growth factor binding protein-1 and insulin-like growth factor binding protein-3. Levels in healthy elderly individuals. Relation to self-reported quality of health and disability. Gerontology. 44:1998;277-280.
113. Blum-Degen D., Frolich L., Hoyer S., Riederer P. Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders? J Neural Transm Suppl. 46:1995;139-147.
114. Auer R. N. Insulin, blood glucose levels, and ischemic brain damage. Neurology. 51 (3 Suppl. 3):1998;S39-43.
115. Duelli R., Schrock H., Kuschinsky W., Hoyer S. Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats. Int J Dev Neurosci. 12:1994;737-743.
116. Li C., Li P., He Q., Quyang Y., Siesjö B. K. Effects of streptozocin-induced hyperglycemia on brain damage following transient ischemia. Neurobiol Dis. 5:1998;117-128.
117. Craft S., Dagogo-Jack S. E., Wiethop B. V. Effects of hyperglycemia on memory and hormone levels in dementia of Alzheimer type: a longitudinal study. Behav Neurosci. 107:1993;926-940.
118. Meneilly G. S., Hill A. Alterations in glucose metabolism in patients with Alzheimer disease. J Am Geriatr Soc. 41:1993;710-714.
119. Wickelgren I. Tracking insulin to the mind. Science. 280:1998;517-519.
120. Hoyer S., Henneberg N., Knapp S., Lannert H., Martin E. Brain glucose metabolism is controlled by amplification and desensitization of the neuronal insulin receptor. Ann NY Acad Sci. 777:1996;374-379.
121. Ott A., Stolk R. P., Hofman A., Vanharskamp F., Grobbee D. E., Breteler M. M. B. Association of diabetes mellitus and dementia - the Rotterdam study. Diabetologia. 39:1996;1392-1397.
122. Leibson C. L., Rocca W. A., Hanson V. A. Risk of dementia among persons with diabetes mellitus - a population based cohort study. Am J Epidemiol. 145:1997;301-308.
123. Smith M. A., Tabaton M., Perry G. Early contribution of oxidative glycation in Alzheimer disease. Neurosci Lett. 217:1996;210-211.
124. Rapoport S. I., Horwitz B., Grady C. L., Haxby J. V., DeCarli C., Shapiro M. B. Abnormal brain glucose metabolism in Alzheimer's disease, as measured by positron emission tomography. Adv Exp Biol Med. 291:1991;231-238.
125. Hoyer S. Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm. 105:1998;415-422.
126. Hall J. L., Gonder-Frederick L. A., Chewning W. W., Silviera J., Gold P. E. Glucose enhancement of performance on memory test in young and aged humans. Neuropsychologia. 9:1989;1129-1138.
127. Manning C. A., Hall J. L., Gold P. E. Glucose effects on memory and other neuropsychological tests in elderly humans. Psych Sci. 1:1990;307-311.
128. McLay R. N., Freeman S. M., Harlan R. E., Ide C. F., Kastin A. J., Zadina J. E. Aging in the hippocampus: interrelated actions of neurotrophins and glucocorticoids. Neurosci Biobeh Rev. 21:1997;615-629.
129. Baura G. D., Foster D. M., Kaiyala K., Porte D. Jr, Kahn S. E., Schwartz M. W. Insulin transport from plasma into the central nervous system is inhibited by dexamethasone in dogs. Diabetes. 45:1996;86-90.
130. Münch G., Schinzel R., Loske C. Alzheimer's disease - synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm. 105:1998;439-461.
131. Yan S. D., Yan S. F., Chen X. Non-enzymatically glycated tau protein in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid-beta peptide. Nature Med. 1:1995;693-699.
132. Yan S. D., Chen A., Schmidt M. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA. 91:1994;7787-7795.
133. Brugg B., Dubreuil Y. L., Huber G., Wollman E. E., Delhaye-Bouchaud N., Mariani J. Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain. Proc Natl Acad Sci USA. 92:1995;3032-3035.
134. Mullarkey C. J., Edelstein D., Brownlee M. Free radical generation by early glycation endproducts: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun. 173:1990;932-939.
135. Gitter B. D., Cox L. M., Rydel R. E., May P. C. Amyloid beta peptide potentiates cytokine secretion by interleukin-1 beta-activated human astrocytoma cells. Proc Natl Acad Sci USA. 92:1995;10738-10741.
136. Hom J. T., Estridge T., Pechous P., Hyslop P. A. The amyloidogenic peptide human amylin augments the inflammatory activities of eosinophils. J Leukoc Biol. 58:1995;526-532.
137. Hatzinger M., Z'Brun A., Hemmeter U. Hypothalamic-pituitary-adrenal system function in patients with Alzheimer's disease. Neurobiol Aging. 16:1995;205-209.
138. Guzdek A., Stalinska K. Glycated proteins as inducers of acute phase cytokines. Fol Histochem Cytobiol. 30:1992;167-169.
139. Fang C. H., Li B. G., James J. H., Fischer J. E., Hasselgren P. O. Cytokines block the effects of insulin-like growth factor-I (IGF-I) on glucose uptake and lactate production in skeletal muscle but do not influence IGF-I-induced changes in protein turnover. Shock. 8:1997;362-367.
140. Nilsson J., Jovinge S., Niemann A., Reneland R., Lithell H. Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 18:1998;1199-1202.
141. Mabley J. G., Belin V., John N., Green I. C. Insulin-like growth factor I reverses interleukin-1beta inhibition of insulin secretion, induction of nitric oxide synthase and cytokine-mediated apoptosis in rat islets of Langerhans. FEBS Lett. 417:1997;235-238.
142. Paz K., Hemi R., LeRoith D. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem. 272:1997;29911-29918.
143. Paolisso G., Rizzo M. R., Mazziotti G. Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am J Physiol. 275:1998;E294-E299.
144. Katsuki A., Sumida Y., Murashima S. Serum levels of tumor-necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 83:1998;859-862.
145. Samstein B., Hoimes M. L., Fan J., Frost R. A., Gelato M. C., Lang C. H. IL-6 stimulation of insulin-like growth factor binding protein (IGFBP)-1 production. Biochem Biophys Res Commun. 228:1996;611-615.
146. Rajkumar K., Krsek M., Dheen S. T., Murphy L. J. Impaired glucose homeostasis in insulin-like growth factor binding protein-1 transgenic mice. J Clin Invest. 98:1996;1818-1825.
147. Rajkumar K., Dheen S. T., Murphy L. J. Hyperglycemia and impaired glucose tolerance in IGF binding protein-1 transgenic mice. Am J Physiol. 270:1996;E565-E571.
148. Skoog I. Status of risk factors for vascular dementia. Neuroepidemiology. 17:1998;2-9.
149. Brayne C., Gill C., Huppert F. A. Vascular risks and incident dementia: results from a cohort study of the very old. Dement Geriatr Cogn Disord. 9:1998;175-180.
150. Liu L. S., Spelleken M., Rohrig K. Tumor necrosis factor-alpha acutely inhibits insulin signaling in human adipocytes: implication off the p80 tumor necrosis factor receptor. Diabetes. 47:1998;515-522.
151. Halle M., Berg A., Northoff H., Keul J. Importance of TNF-alpha and leptin in and insulin resistance: a hypothesis on the impact of physical exercise. Exerc Immunol Rev. 4:1998;77-94.
152. Marfaing-Jallat P., Levacher C., Calando Y., Picon L., Penicaud L. Glucose utilization and insulin binding in discrete brain areas of obese rats. Physiol Behav. 52:1992;713-716.
153. Cacabelos R., Alvarez X. A., Franco-Maside A., Fernandez-Novoa L., Caamano J. Serum tumor necrosis factor (TNF) in Alzheimer's disease and multi-infarct dementia. Methods Find Exp Clin Pharmacol. 16:1994;29-35.
154. Frölich L., Blum-Dergen D., Bernstein H. G. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm. 105:1998;423-428.
155. Hopkins D. F., Williams G. Insulin receptors are widely distributed in human brain and bind human and porcine insulin with equal affinity. Diabet Med. 14:1997;1044-1050.
156. Hoyer S. Oxidative metabolism deficiencies in brains of patients with Alzheimer's disease. Acta Neurol Scand Suppl. 165:1996;18-24.
157. Frattali A. L., Treadway J. L., Pessin J. E. Insulin/IGF-1 hybrid receptors: implications for the dominant-negative phenotype in syndromes of insulin resistance. J Cell Biochem. 48:1992;43-50.
158. Krook A., O'Rahilly S. Mutant insulin receptors in syndromes of insulin resistance. Baillières Clin Endocrinol Metab. 10:1996;97-122.
159. Karagiannis S. N., King R. H., Thomas P. K. Colocalisation of insulin and IGF-1 receptors in cultured rat sensory and sympathetic ganglion cells. J Anat. 191:1997;431-440.
160. Bailyes E. M., Nave B. T., Soos M. A., Orr S. R., Hayward A. C., Siddle K. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptors species by selective immunoprecipitation and immunoblotting. Biochem J. 327:1997;209-215.
161. Pessin J. E., Frattali A. L. Molecular dynamics of insulin/IGF-I receptor transmembrane signaling. Mol Reprod Dev. 35:1993;339-344.
162. Tham A., Nordberg A., Grissom F. E., Carlsson-Skwirut C., Viitanen M., Sara V. R. Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J Neural Transm Park Dis Dement Sect. 5:1993;165-176.
163. 125I]-insulin-like growth factor-1 (IGF-1) in brains of Alzheimer's and alcoholic patients. Adv Exp Med Biol. 293:1991;483-492.
164. Cortizo A. M., Gagliardino J. J. Protein glycation: its role in the changes induced by diabetes in the properties of thef serum insulin-like growth factor binding proteins. J Endocrinol. 131:1991;33-38.
165. Lupien S., Lecours A. R., Schwartz G. Longitudinal study of basal cortisol levels in healthy elderly subjects: evidence for subgroups. Neurobiol Aging. 17:1996;95-105.
166. James K., Premchand N., Skibinska A., Skibinski G., Nicol M., Mason J. I. IL-6, DHEA and the ageing process. Mech Ageing Dev. 93:1997;15-24.
167. Birkenhager-Gillesse E. G., Derksen J., Lagaay A. M. Dehydroepiandrosterone sulphate (DHEAS) in the oldest old, aged 85 and over. Ann NY Acad Sci. 719:1994;543-552.
168. Seck T., Scheidt-Nave C., Ziegler R., Pfeilschifter J. Positive association between circulating free thyroxine and insulin-like growth factor 1 concentrations in euthyroid elderly individuals. Clin Endocrinol. 48:1998;361-366.
169. Radetti G., Drei F., Betterle C., Mengarda G. Down's syndrome, hypothyroidism and insulin-dependent diabetes mellitus. Helv Paediatr Acta. 41:1986;377-380.
170. Stein G. R., Jewell R. C. Down's syndrome, hypothyroidism and diabetes mellitus in an adult. Med J Aust. 2:1979;9-10.
171. Dugbartey A. T. Neurocognitive aspects of hypothyroidism. Arch Intern Med. 158:1998;1413-1418.
172. Espino D. V., Jules-Bradley A. C., Johnston C. L., Mouton C. P. Diagnostic approach to the confused elderly patient. Am Fam Physician. 57:1998;1358-1366.
173. Regelson W., Harkins S. W. "Amyloid is not a tombstone" - a summation. The primary role for cerebrovascular and CSF dynamics as factors in Alzheimer's disease (AD): DMSO, fluorocarbon oxygen carriers, thyroid hormonal, and other suggested therapeutic measures. Ann NY Acad Sci. 826:1997;348-374.
174. Shetty K. R., Duthie E. H. Jr. Thyroid disease and associated illness in the elderly. Clin Geriatr Med. 11:1995;311-325.
175. Nolan K. A., Blass J. P. Preventing cognitive decline. Clin Geriatr Med. 8:1992;19-34.
176. Miura S., Iitaka M., Suzuki S. Decrease in serum levels of thyroid hormone in patients with coronary heart disease. Endocr J. 43:1996;657-663.
177. Pekary A. E., Hershman J. M. Tumor necrosis factor, ceramide, transforming growth factor-beta1, and aging reduce Na+/I- symporter messenger ribonucleic acid levels in FRTL-5 cells. Endocrinology. 139:1998;703-712.
178. Rondeel J. M., deGreef W. J., Heide R., Visser T. J. Hypothalamo-hypophysial-thyroid axis in streptozotocin-induced diabetes. Endocrinology. 130:1992;216-220.
179. Valimaki M., Liewendahl K., Nikkanen P., Pelkonen R. Hormonal changes in severely uncontrolled type 1 (insulin-dependent) diabetes mellitus. Scand J Clin Lab Invest. 51:1991;385-393.
180. Murai H., Murakami S., Ishida K., Sugawara M. Elevated serum interleukin-6 and decreased thyroid hormone levels in postoperative patients and effects of IL-6 on thyroid cell function in vitro. Thyroid. 6:1996;601-606.
181. Reimers J. I., Rasmussen A. K., Karlsen A. E. Interleukin-1 beta inhibits rat thyroid cell function in vivo and in vitro by an NO-independent mechanism and induces hypothyroidism and accelerated thyroiditis in diabetes-prone BB rats. J Endocrinol. 151:1996;147-157.
182. Wolf M., Hansen N., Greten H. Interleukin 1 beta, tumor necrosis factor-alpha and interleukin 6 decrease nuclear thyroid hormone receptor capacity in a liver cell line. Eur J Endocrinol. 131:1994;307-312.
183. Bartalena L., Grasso L., Brogioni S., Martino E. Interleukin 6 effects on the pituitary-thyroid axis in the rat. Eur J Endocrinol. 131:1994;302-306.
184. Latasa M. J., Belandia B., Pascual A. Thyroid hormones regulate beta-amyloid gene splicing and protein secretion in neuroblastoma cells. Endocrinology. 139:1998;2692-2698.